Apr 16, 2021 / 12:00PM GMT
Operator
Good morning, and welcome to the Mersana Therapeutics conference call. (Operator Instructions) I would now like to turn the call over to Sarah Carmody, Executive Director, Investor Relations and Corporate Communications. Please proceed.
Sarah Carmody - Mersana Therapeutics, Inc. - Executive Director of IR & Corporate Communications
Good morning. Welcome to Mersana's conference call and webcast to discuss the selection of the NaPi2b biomarker cutoff and our commercial diagnostic development path. A replay of today's call will be available on the Investors and Media section of our website. After our prepared remarks, we will open the call for Q&A.
Before we begin, I'd like to mention that our call will contain forward-looking statements within the meaning of federal securities laws. These are not statements of historical facts and are based on management's beliefs and assumptions and on information currently available. They are subject to risks and uncertainties that could cause the actual results and the implementation of the company's plans to
Mersana Therapeutics Inc Selection of the NaPi2b Biomarker Cutoff and Commercial Diagnostic Development Path - Corporate Call Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot